Arbutus Biopharma Corporation (NASDAQ:ABUS) marked $2.46 per share on Wednesday, up from a previous closing price of $2.30. While Arbutus Biopharma Corporation has overperformed by 6.96%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABUS fell by -10.55%, with highs and lows ranging from $6.50 to $1.93, whereas the simple moving average fell by -19.54% in the last 200 days.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Sponsored
On February 02, 2022, Jefferies Upgraded Arbutus Biopharma Corporation (NASDAQ: ABUS) to Buy. A report published by Jefferies on February 25, 2021, Initiated its previous ‘Hold’ rating for ABUS. H.C. Wainwright also rated ABUS shares as ‘Buy’, setting a target price of $10 on the company’s shares in an initiating report dated December 17, 2020. JMP Securities Initiated an Mkt Outperform rating on July 27, 2020, and assigned a price target of $8. Robert W. Baird July 24, 2020d its ‘Outperform’ rating to ‘Neutral’ for ABUS, as published in its report on July 24, 2020. Chardan Capital Markets also rated the stock as ‘Buy’.
Analysis of Arbutus Biopharma Corporation (ABUS)
Further, the quarter-over-quarter increase in sales is 500.00%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Arbutus Biopharma Corporation’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -135.60% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.02M can be a very valuable indicator of volatility for ABUS stock. On a monthly basis, the volatility of the stock is set at 5.49%, whereas on a weekly basis, it is put at 5.73%, with a gain of 2.50% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.50, showing growth from the present price of $2.46, which can serve as yet another indication of whether ABUS is worth investing in or should be passed over.
How Do You Analyze Arbutus Biopharma Corporation Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 27.11%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 29.80% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ABUS shares?
The recent increase in stakes in ABUS appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in ABUS has increased by 10.90% in the first quarter. The company now owns 6,288,684 shares of the stock, with a value of $17.04 million, following the purchase of 618,213 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in ABUS during the first quarter, upping its stake by 4.33%. During the last quarter, the company picked up 193,243 additional shares for a total stake of worth $12.61 million, bringing number of shares owned by the company to 4,654,871.
During the first quarter, Hudson Bay Capital Management LP added a 2,677,627 position in ABUS. Brookfield Public Securities Grou purchased an additional 1.14 million shares in the last quarter, increasing its holdings by 95.16%, now holding 2.33 million shares worth $6.31 million. At the end of the first quarter, Two Seas Capital LP increased its ABUS holdings by 166.37% and now holds 2.2 million ABUS shares valued at $5.96 million with the added 1.37 million shares during the period. ABUS shares are owned by institutional investors to the tune of 29.80% at present.
